Spyre Therapeutics Inc
SYRE32.760USD
+0.880+2.76%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
1.98BMarket Cap
LossP/E TTM
More Details of Spyre Therapeutics Inc Company
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Spyre Therapeutics Inc Info
Ticker SymbolSYRE
Company nameSpyre Therapeutics Inc
IPO dateApr 07, 2016
CEOTurtle (Cameron)
Number of employees65
Security typeOrdinary Share
Fiscal year-endApr 07
Address221 Crescent Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone
Websitehttps://spyre.com/
Ticker SymbolSYRE
IPO dateApr 07, 2016
CEOTurtle (Cameron)
Company Executives of Spyre Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
687.54K
-2.14%
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
406.04K
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
27.36K
-20.37%
Dr. Sheldon Sloan
Dr. Sheldon Sloan
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Heidy Abreu King-Jones, J.D.
Ms. Heidy Abreu King-Jones, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
--
--
Mr. Eric Mcintyre
Mr. Eric Mcintyre
Investor Relations
Investor Relations
--
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Director
Director
--
--
Ms. Laurie D. Stelzer, CPA
Ms. Laurie D. Stelzer, CPA
Independent Director
Independent Director
--
--
Mr. Scott L. Burrows, CPA
Mr. Scott L. Burrows, CPA
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
687.54K
-2.14%
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
406.04K
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
27.36K
-20.37%
Dr. Sheldon Sloan
Dr. Sheldon Sloan
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Heidy Abreu King-Jones, J.D.
Ms. Heidy Abreu King-Jones, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.56%
Fairmount Funds Management LLC
5.18%
RTW Investments L.P.
4.67%
BlackRock Institutional Trust Company, N.A.
4.63%
Deutsch (Peter E)
4.58%
Other
69.39%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.56%
Fairmount Funds Management LLC
5.18%
RTW Investments L.P.
4.67%
BlackRock Institutional Trust Company, N.A.
4.63%
Deutsch (Peter E)
4.58%
Other
69.39%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.54%
Hedge Fund
22.70%
Investment Advisor/Hedge Fund
20.77%
Individual Investor
6.70%
Research Firm
3.77%
Venture Capital
3.46%
Private Equity
1.58%
Pension Fund
0.18%
Bank and Trust
0.18%
Other
9.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
298
65.04M
85.30%
-7.71M
2025Q2
294
72.36M
119.81%
+322.00K
2025Q1
303
71.05M
117.75%
+125.57K
2024Q4
285
66.15M
109.77%
+5.27M
2024Q3
266
53.78M
104.74%
-3.29M
2024Q2
236
52.59M
103.65%
+11.50M
2024Q1
227
33.78M
92.59%
-505.83K
2023Q4
200
30.14M
83.90%
+18.94M
2023Q3
198
4.06M
102.41%
-373.56K
2023Q2
204
3.01M
94.95%
+483.40K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
8.61M
14.25%
+373.60K
+4.54%
Jun 30, 2025
Fairmount Funds Management LLC
4.02M
6.65%
--
--
Jun 30, 2025
RTW Investments L.P.
3.62M
6%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.58M
5.93%
+369.56K
+11.50%
Jun 30, 2025
Deutsch (Peter E)
3.55M
5.88%
+3.17M
+825.37%
Oct 14, 2024
Tang Capital Management, LLC
3.20M
5.3%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.06M
5.06%
+168.32K
+5.82%
Jun 30, 2025
VR Adviser, LLC
2.69M
4.45%
--
--
Jun 30, 2025
Braidwell LP
2.58M
4.27%
--
--
Jun 30, 2025
Capital International Investors
2.39M
3.96%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
State Street SPDR S&P Biotech ETF
0.49%
First Trust Multi-Manager Small Cap Opportunities ETF
0.48%
Optimize Strategy Index ETF
0.32%
ProShares Ultra Nasdaq Biotechnology
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.22%
Invesco Nasdaq Biotechnology ETF
0.15%
iShares Biotechnology ETF
0.11%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.08%
iShares Morningstar Small-Cap Value ETF
0.06%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.94%
State Street SPDR S&P Biotech ETF
Proportion0.49%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.48%
Optimize Strategy Index ETF
Proportion0.32%
ProShares Ultra Nasdaq Biotechnology
Proportion0.22%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.22%
Invesco Nasdaq Biotechnology ETF
Proportion0.15%
iShares Biotechnology ETF
Proportion0.11%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.08%
iShares Morningstar Small-Cap Value ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 07, 2023
Merger
25→1
Sep 07, 2023
Merger
25→1
Sep 07, 2023
Merger
25→1
Sep 07, 2023
Merger
25→1
Date
Type
Ratio
Sep 07, 2023
Merger
25→1
Sep 07, 2023
Merger
25→1
Sep 07, 2023
Merger
25→1
Sep 07, 2023
Merger
25→1
FAQs
Who are the top five shareholders of Spyre Therapeutics Inc?
The top five shareholders of Spyre Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 8.61M shares, accounting for 14.25% of the total shares.
Fairmount Funds Management LLC holds 4.02M shares, accounting for 6.65% of the total shares.
RTW Investments L.P. holds 3.62M shares, accounting for 6.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.58M shares, accounting for 5.93% of the total shares.
Deutsch (Peter E) holds 3.55M shares, accounting for 5.88% of the total shares.
Fidelity Management & Research Company LLC holds 8.61M shares, accounting for 14.25% of the total shares.
Fairmount Funds Management LLC holds 4.02M shares, accounting for 6.65% of the total shares.
RTW Investments L.P. holds 3.62M shares, accounting for 6.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.58M shares, accounting for 5.93% of the total shares.
Deutsch (Peter E) holds 3.55M shares, accounting for 5.88% of the total shares.
What are the top three shareholder types of Spyre Therapeutics Inc?
The top three shareholder types of Spyre Therapeutics Inc are:
Fidelity Management & Research Company LLC
Fairmount Funds Management LLC
RTW Investments L.P.
Fidelity Management & Research Company LLC
Fairmount Funds Management LLC
RTW Investments L.P.
How many institutions hold shares of Spyre Therapeutics Inc (SYRE)?
As of 2025Q3, 298 institutions hold shares of Spyre Therapeutics Inc, with a combined market value of approximately 65.04M, accounting for 85.30% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -34.51%.
What is the biggest source of revenue for Spyre Therapeutics Inc?
In --, the -- business generated the highest revenue for Spyre Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
